Rozlytrek Becomes the Third Tumor-Agnostic Medicine to be Approved by the USFDA
By Rajaneesh K. Gopinath, Ph.D. After Merck and Co’s Keytruda and Bayer and Loxo Oncology’s Vitrakvi, Roche’s Rozlytrek (Entrectinib) bags USFDA approval as an oncology therapy, that is not specific …
Read More